Furthermore, we performed immunohistochemistry analysis and confirmed the high expression of SNX3 in saline and cetuximab groups, along with low expression of p62, when compared to honokiol and honokiol + cetuximab groups in orthotopic KRASG13D mutant tumor sections (Figure 7M). Here, SNX3 is linked to neoplasm.